Besides mTORC1 inhibition, AMPK has been also shown to promote p53 activation via phosphorylation of Ser15, thus promoting cell survival in response to glucose limitation [171] and p53-deficient cancer cells were shown to be more sensitive to metformin treatment [172], indicating that p53 regulates cancer cells survival in response to metformin-induced metabolic changes. The gene discussed is PRKAA1; the disease is cancer.